Grant: Planning and Dissemination Grant - Institute Community Support
Centre hospitalier de l'Université de Montréal (CHUM)
$15,000.00
The liver-brain axis in metabolic dysfunction-associated steatotic liver disease symposium
FY 2024-25
Summary
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects 30% of the population world wide, touching close to 8 million Canadians. MASLD represents a spectrum of disease severity spanning from simple accumulation of fat in the liver to liver inflammation which leads to an increased risk of liver cirrhosis and liver cancer. MASLD is defined as fat buildup in the liver with at least one of five cardiometabolic risk factors (obesity, insulin resistance, hypertension, hypertriglyceridaemia or hypercholesterolaemia), and an average daily alcohol intake (<20 g for females; <30 g for males). In addition, the presence of MASLD leads to an increased risk of type 2 diabetes mellitus, cardiovascular disease and other metabolic consequences, defining MASLD as a multisystem disease.
Recent interest has emerged in exploring the liver-brain axis in MASLD, since patients with MASLD have been diagnosed with cognitive problems. The reasons why brain health is impacted lie within the causes and consequences of MASLD, including low-grade inflammation, altered metabolism of lipids, changes in gut microbiota and insulin resistance.
This international symposium will focus on the liver-brain axis in MASLD. We propose to integrate this international scientific symposium within the International Society of Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) to be held in Quebec, Canada (organized by Dr. Rose). The goal is to continue to talk about this major health issue and develop and strengthen collaborations between international and Canadian experts in the field of liver-brain axis. This symposium will reveal new results and data in the field and new developments on how the brain is affected during MASLD will be discussed and new ideas on how to improve the management and treat patients suffering from MASLD will be discovered. In the end, a consensus report will be written disseminating and highlighting the best of the symposium and identify future areas of research.
Department
Program
Planning and Dissemination Grant - Institute Community Support
Location
Quebec, Canada
Recipient Type
Not-for-profit organization or charity
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
508345
Name
Rose Christopher
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Planning and Dissemination Grants
Projecttitle
The liver-brain axis in metabolic dysfunction-associated steatotic liver disease symposium
Programtype2
Miscellaneous Programs
Orgnameinp2
Centre hospitalier de l'Université de Montréal (CHUM)
Cihramount2
$15,000
Cihrequipment2
$0
Programname2
Planning and Dissemination Grant - Institute Community Support
Keyworddelim
Ammonia; Cerebral Metabolism; Dyslipidemia; Liver Metabolism; Liver-Brain Axis; Malnutrition; Metabolic Dysfunction-Associated Steatotic Liver Disease; Systemic Inflammation
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects 30% of the population world wide, touching close to 8 million Canadians. MASLD represents a spectrum of disease severity spanning from simple accumulation of fat in the liver to liver inflammation which leads to an increased risk of liver cirrhosis and liver cancer. MASLD is defined as fat buildup in the liver with at least one of five cardiometabolic risk factors (obesity, insulin resistance, hypertension, hypertriglyceridaemia or hypercholesterolaemia), and an average daily alcohol intake (<20 g for females; <30 g for males). In addition, the presence of MASLD leads to an increased risk of type 2 diabetes mellitus, cardiovascular disease and other metabolic consequences, defining MASLD as a multisystem disease.
Recent interest has emerged in exploring the liver-brain axis in MASLD, since patients with MASLD have been diagnosed with cognitive problems. The reasons why brain health is impacted lie within the causes and consequences of MASLD, including low-grade inflammation, altered metabolism of lipids, changes in gut microbiota and insulin resistance.
This international symposium will focus on the liver-brain axis in MASLD. We propose to integrate this international scientific symposium within the International Society of Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) to be held in Quebec, Canada (organized by Dr. Rose). The goal is to continue to talk about this major health issue and develop and strengthen collaborations between international and Canadian experts in the field of liver-brain axis. This symposium will reveal new results and data in the field and new developments on how the brain is affected during MASLD will be discussed and new ideas on how to improve the management and treat patients suffering from MASLD will be discovered. In the end, a consensus report will be written disseminating and highlighting the best of the symposium and identify future areas of research.
Competitiondate
202408
Approvedterm2
1 yr 0 mth
Pinamesdelim
Rose, Christopher
Approvedterm
1 an 0 mois
Cihrcontribution2
INMD~ $15,000~ $0~